Evidence map›Paper›PMID 39448999›Full record

Trial reportBMC health services research2024

Acceptability of six-monthly PrEP dispensing supported with interim HIV self-testing to simplify PrEP delivery in Kenya: findings from qualitative research.

Nicholas Thuo, Ashley R Bardon, Peter Mogere, Catherine Kiptinness, Edinah Casmir, Njeri Wairimu, Emmah Owidi, Phelix Okello, Nelly R Mugo, Jared M Baeten and 2 more

Registry-linked trialAbstract readRandomized Controlled TrialEquivalence Trial
In one paragraph

Trial report in BMC health services research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03593629 (HIV Self-Testing to Improve the Efficiency of PrEP Delivery), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03593629 nacompletednot on this map

HIV Self-Testing to Improve the Efficiency of PrEP Delivery

TypeinterventionalSponsorUniversity of WashingtonRan2018 to 2021Enrolled790ConditionsHIV-1-infectionArms6-month PrEP + blood-based HIV self-test, 6-month PrEP + oral fluid HIV self-test
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Acceptability, Facilitators, and Barriers of Long-Acting Injectable Cabotegravir/Rilpivirine Among Youth With HIV in the United States.The Journal of adolescent health : official publication of the Society for Adolescent Medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nicholas ThuoPartners in Health Research and Development, Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya. nbthuo@pipsthika.org.
Ashley R BardonDepartment of Global Health, University of Washington, Seattle, USA.
Peter MogerePartners in Health Research and Development, Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
Catherine KiptinnessPartners in Health Research and Development, Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
Edinah CasmirPartners in Health Research and Development, Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
Njeri WairimuPartners in Health Research and Development, Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
Emmah OwidiPartners in Health Research and Development, Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
Phelix OkelloPartners in Health Research and Development, Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
Nelly R MugoPartners in Health Research and Development, Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
Jared M BaetenDepartment of Global Health, University of Washington, Seattle, USA.
Kenneth Ngure *School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Katrina F Ortblad *Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
HIV self-testing to improve the efficiency of PrEP deliveryR01MH113572 · NIMH · UNIVERSITY OF WASHINGTON · PI MUGO, NELLY RWAMBA, NGURE, KENNETH · 2018 to 2021
$2.2M
Peer PrEP referral + HIV self-test for PrEP initiation among young Kenyan womenR00MH121166 · NIMH · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ORTBLAD, KATRINA FRANCES · 2021 to 2024
$866k
NIAID NIH HHS P30 AI027757NIMH NIH HHS R00 MH121166NIMH NIH HHS R01 MH113572
6 · The paper itself

Abstract

backgroundIn Africa, dispensing oral HIV pre-exposure prophylaxis (PrEP) within already strained public health facilities has led to prolonged waiting periods and suboptimal experiences for clients. We sought to explore the acceptability of dispensing PrEP semiannually with interim HIV self-testing (HIVST) versus quarterly PrEP dispensing with clinic-based HIV testing to optimize clinic-delivered PrEP services.

methodsWe conducted a qualitative study within a non-inferiority individual-level randomized controlled trial testing the effect of six-monthly PrEP dispensing with HIVST compared to the standard-of-care three-monthly PrEP dispensing on PrEP clinical outcomes in Kenya (ClinicalTrials.gov: NCT03593629). Eligible participants were ≥ 18 years, refilling PrEP for the first time, and either in an HIV serodifferent relationship (men and women) or singly enrolled (women only). A subset of participants in the intervention group completed serial in-depth interviews (IDIs) at enrollment, six months, and 12 months. We utilized stratified purposive sampling to ensure representation across participant groups. We analyzed our qualitative data thematically using a combination of inductive and deductive approaches, the latter guided by the Theoretical Framework of Acceptability (TFA).

resultsBetween May 2018 and June 2021, we conducted 120 serial IDIs with 55 participants; 64% (35/55) were in a serodifferent relationship, 64% (35/55) were women, and the median age was 32 years (IQR 27-40). Overall, participants found this novel PrEP delivery model highly acceptable; it was well-liked, private (TFA construct: affective attitude), and less burdensome (TFA construct: burden) compared to standard PrEP delivery. Additionally, participants were confident in their ability to participate in the intervention (TFA construct: self-efficacy). Some participants, however, highlighted model disadvantages, including fewer opportunities for in-person counseling and potentially less accurate HIV testing (TFA construct: opportunity costs). Ultimately, most participants reported that the intervention allowed them to achieve their HIV prevention goals (TFA construct: perceived effectiveness) and that their confidence in at-home HIVST and PrEP continuation increased following each semiannual clinic visit.

conclusionsSemiannual PrEP clinic visits supported with six-monthly drug dispensing and interim HIVST was acceptable among PrEP users who experienced the intervention in Kenya. More comprehensive pre-intervention counseling and training on HIVST may help alleviate the client concerns presented, which were often resolved over time with intervention experience.

Indexed as

HIV InfectionsPatient Acceptance of Health CarePre-Exposure ProphylaxisQualitative ResearchSelf-TestingAdultAnti-HIV AgentsFemaleHIV TestingHumansInterviews as TopicKenyaMaleYoung AdultAnti-HIV AgentsAcceptabilityDifferentiated service deliveryHIV self-testingImplementation scienceMulti-month drug dispensingPrEP

Identifiers

PMID39448999
PMCPMC11515400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.